Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Guillain-Barré syndrome in Colombia: where do we stand now?
Long-Term Results Underscore Value of Early MS Treatment
Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.
Raltegravir (Isentress) pilot study in relapsing multiple sclerosis (INSPIRE)
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Genzyme to Resubmit LemtradaTM Application for FDA Review
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.
Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter.
Placebo? no thanks, it might be bad for me!
Submembranous cytoskeletons stabilize nodes of Ranvier.
MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI.
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Simvastatin shows promise in treating progressive multiple sclerosis, study finds.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
Review of MR elastography applications and recent developments.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Astrocytes Underlie Neuroinflammatory Memory Impairment.
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].

Pages